Generalisability of trials on antithrombotic treatment intensification in patients with cardiovascular disease.

Maria C CastelijnsSteven H J HagemanMartin TeraaManon G van der MeerJan WesterinkJurrien M Ten Berg Frank L J Visseren

Published in: Heart (British Cardiac Society) (2024)

A large proportion of contemporary CVD patients would be eligible for intensified antithrombotic treatment trials, with mostly similar adjusted event risks to ineligible patients. Trial-based guideline recommendations are largely applicable to real-world patients.

Keyphrases

end stage renal disease
cardiovascular disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
atrial fibrillation
type diabetes
randomized controlled trial
metabolic syndrome
risk assessment
patient reported outcomes
combination therapy